Ross Moat - 07 Apr 2022 Form 4 Insider Report for Kiniksa Pharmaceuticals, Ltd. (KNSA)

SEC form
4
Accepted by SEC
11 Apr 2022, 16:30:41 UTC
Prior SEC filing
23 Mar 2022
Next SEC filing
06 Sep 2022
Source filing
View source filing
Filing notes and source

Key filing fact

Ross Moat filed Form 4 for Kiniksa Pharmaceuticals, Ltd. (KNSA) on 11 Apr 2022.

Key facts

  • This page summarizes Ross Moat's Form 4 filing for Kiniksa Pharmaceuticals, Ltd. (KNSA).
  • 2 reported transactions and 2 derivative rows are listed below.
  • Accepted by SEC: 11 Apr 2022, 16:30.

Change

  • Previous filing in this sequence was filed on 23 Mar 2022.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

KNSA transaction Derivative

Share Option

Award

Transaction value
$0
Shares
+59,460
Change %
Price
$0.000000
Shares after
59,460
Date
07 Apr 2022
Ownership
Direct
Underlying class
Class A Common Share
Underlying amount
59,460
Exercise price
$11.10
Footnotes
F1
KNSA transaction Derivative

Restricted Share Unit

Award

Transaction value
$0
Shares
+9,908
Change %
Price
$0.000000
Shares after
9,908
Date
07 Apr 2022
Ownership
Direct
Underlying class
Class A Common Share
Underlying amount
9,908
Exercise price
Footnotes
F2, F3
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April 7, 2022.

Footnote F2

Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer.

Footnote F3

The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 7, 2022.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .